EUVIMEDEUVIMED entdecken
Qualitative StudieOpen Access · CC BY 4.0

How Is Equity Considered Within National Healthcare Priority Setting? A Qualitative Study of Australian Health Technology Assessment Actors' Perspectives

Sheridan Rodda iD, Melanie Lloyd iD, Aili Langford iD, Jedidiah Morton, Zanfina Ademi iD

Health Expectations · 2026-12 · 29 (6)

DOI: 10.1111/hex.70955 ↗

Kurz gefasst

Qualitative Studie in der Zeitschrift Health Expectations, online erschienen am 30.10.2026. Verfasst von Sheridan Rodda und 4 weiteren Autor:innen. Beteiligte Einrichtung: Grad Dip Health Ec and Policy, Health Economics and Policy Evaluation Research group, Faculty of Pharmacy and Pharmaceutical Sciences, Monash Univers…. Hauptthemen laut MEDLINE: Technology Assessment, Biomedical, Health Priorities, Decision Making, Health Equity. Die Arbeit nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian Government, Monash University, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Equity is recognised in the decision‐making within Australian health technology assessment (HTA), although limited studies describe how these considerations are operationalised in practice. We aimed to explore the experiences and views of a range of HTA actors, to understand how equity is considered in HTA processes.

Methods

Semi‐structured interviews were conducted with 21 participants including sponsors, members of patient or consumer representative groups, non‐government organisations and interest groups, economists preparing or assessing HTA submissions and people in government‐appointed roles, including HTA committee members. Interview transcripts were analysed using reflexive thematic analysis.

Results

Reflexive thematic analysis produced three overarching themes. Firstly, equity can be considered in decision‐making, but its role is not transparent, and equity meaningfully impacts decision‐making in few circumstances. Secondly, there are institutional, ideological and methodological challenges that impede the consideration of equity in HTA. Ambiguous guidance and public summary documents mean the inclusion, evaluation and appraisal of equity‐relevant information depends on the individual, creating inconsistency. In the absence of a clear equity definition, HTA actors frame equity in ways that serve their own purposes, creating confusion and tension within a reactive process. Decision‐makers face a dilemma between evidence‐based medicine paradigms, which predominate, and patient or lived experience evidence. Limited knowledge of public values on equity priorities constrains decision‐maker ability to integrate equity concerns into recommendations. Thirdly, HTA actors express a preference for incremental and pragmatic HTA reform. They wish to maintain a deliberative approach to decision‐making with qualitative equity information but see scope to adopt strategies such as Citizens' juries or case studies trialling the use of equity‐informed economic evaluations.

Conclusions

This study constructed a detailed understanding of how equity is considered by HTA actors, the challenges faced, and generated potential strategies to better consider equity in Australian HTA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Technology Assessment, BiomedicalHealth PrioritiesDecision MakingHealth EquityHumansAustraliaQualitative ResearchInterviews as Topic

Stichwörter der Autor:innen

decision‐makingequityhealth policyhealth technology assessment (HTA)inequalityqualitative research

Autor:innen und Institutionen

  • Grad Dip Health Ec and Policy, Health Economics and Policy Evaluation Research group, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Australia.
  • Health Economics and Policy Evaluation Research group, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Australia.
  • Murdoch Children's Research Institute, Parkville, Australia.
  • Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
  • Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Australia.
  • Baker Heart and Diabetes Institute, Melbourne, Australia.

ORCID-Profile: Sheridan Rodda, Melanie Lloyd, Aili Langford, Zanfina Ademi

Förderung

  • Australian Government
  • Monash University
  • National Health and Medical Research Council

Zitieren

APA

Rodda, S., Lloyd, M., Langford, A., Morton, J., & Ademi, Z. (2026). How Is Equity Considered Within National Healthcare Priority Setting? A Qualitative Study of Australian Health Technology Assessment Actors' Perspectives. Health Expectations, 29(6). https://doi.org/10.1111/hex.70955

Vancouver

Rodda S, Lloyd M, Langford A, Morton J, Ademi Z. How Is Equity Considered Within National Healthcare Priority Setting? A Qualitative Study of Australian Health Technology Assessment Actors' Perspectives. Health Expectations. 2026;29(6). doi:10.1111/hex.70955

BibTeX
@article{Rodda2026,
  author = {Rodda, Sheridan and Lloyd, Melanie and Langford, Aili and Morton, Jedidiah and Ademi, Zanfina},
  title = {How Is Equity Considered Within National Healthcare Priority Setting? A Qualitative Study of Australian Health Technology Assessment Actors' Perspectives},
  journal = {Health Expectations},
  year = {2026},
  volume = {29},
  number = {6},
  doi = {10.1111/hex.70955}
}
Kostenlos starten →